Our Patient Value Strategy
In 2015, UCB has embarked on a very important change journey guided by our Patient Value Strategy.
This evolution from the traditional pharma model was critical for us to remain competitive and sustainable for the long-term in an increasingly complex and value-focused healthcare environment. Our operating model from scientific innovation to clinical development and commercialization is based on understanding the patient environment to deliver compelling value propositions in partnership with stakeholders.
From Solution to Patient
We strive for a unique patient experience, providing solutions with the highest possible impact.
From Patient to Science
We pursue a deep understanding of patient sub-populations to develop an original scientiﬁc hypothesis.
From Science to Solution
We aim to translate scientiﬁc hypotheses into innovative solutions and engage patients in the journey.
Inspired by patients…
We start research from the patients’ perspective rather than commencing from a pure scientiﬁc point of view. We listen to patients to encompass the full impact of the disease: the unpredictability, the physical effects and the heavy social stigma… They affect every part of a patient’s life, including their education, employment and independence. It also has a major impact on their family.
Understanding the patient’s journey: from the first symptoms to the correct diagnosis can take years and patients go through a lot of emotions – both positive and negative. By understanding the impact of their condition on their daily lives, we can all make a positive change in the lives of those who face similar challenges.
No matter how hopeless this battle might appear at first, it is possible to fight back and manage it.
Even though there are similarities, a disease can manifest itself in different ways for different patients. Think about epilepsy: to date, more than 30 different types of seizures have been identiﬁed1. One thing patients living with epilepsy have in common: they all want to get seizures under control – a primary goal leading to a higher quality of life2. We cannot go for a “one fits all” approach anymore.
… Driven by science
Innovation is a key component of our strategy, generating insights that can be translated into clinical differentiation in the next step.
The discovery and development of new drugs is a lengthy and complicated process. Yet it is an essential part of what we do: our science has already delivered solutions for people with severe chronic diseases in the fields of immunology and neurology – but we know there is still a need for new treatments and cures. To fuel innovation, UCB continues to invest more than 20% of its revenue in “R&D”.
However, UCB is also pragmatic and humble enough to recognize that one company, even one as dynamic as UCB, cannot conquer severe diseases on its own. We focus our resource where we can make a real difference and out-license pipeline assets in areas where UCB cannot lead. We collaborate in several hundred alliances, ranging from partnerships with European and U.S. academic groups to multiple industrial agreements, as well as memberships in major government-led consortia. Thanks to this network, UCB teams can share and gain knowledge – sometimes leading to acquisitions, such as Beryllium or Element Genomics, or spin-offs like Syndesi Therapeutics.
Our business model starts and ends with the patient.
We combine patient insights with science, translating them into solutions. However, to create value for patients we must also ensure they have access to UCB solutions! UCB’s patient value strategy takes root in our ambition to improve patients’ lives through dedicated treatments, medications – and services while adapting to speciﬁc dynamics and stakeholder inﬂuences in local patient environments. On our website, we provide information on our sponsored clinical studies giving patients the opportunity to make informed decisions about participating in UCB’s clinical studies. We created UCBCares®, a dedicated service to support patients through their treatment journey beyond medical information.
With the Patient Value Strategy, UCB aims to deliver unique outcomes and the best patient experience to as many lives as possible within speciﬁc populations. UCB will only commercialize assets where we can have the biggest impact. If we are not in that position of strength, we will partner to unleash that value.
Entering the 2nd phase of our strategy
UCB has a clear long-term strategy to realize its ambition of becoming the Patient-Preferred Biopharma Leader. In 2019 we will enter the second phase of this strategy, named “Accelerate & Expand”. We continue our dialogue with patients and healthcare professionals to ensure our solutions will truly make a difference, with a strong focus on specific patient groups who will benefit most from UCB medicines.
Grow & Prepare
- More than 3.3 million patients use our core medicines compared to 2.3 million (2015).
- We progressed our pipeline assets:
- Briviact® was launched in 2016
- romosozumab evolved from Phase 3 to filing stage
- bimekizumab completed Phase 2b and entered Phase 3
- padsevonil completed Phase 2a and entered Phase 2b
- We paved the way:
- Cimzia® in psoriasis – preparing for bimekizumab
- romosozumab in osteoporosis
- midazolam in acute repetitive seizures
- We enhanced our financials and strategic flexibility:
- Revenue grew by 20%, from € 3.87 billion (2015) to € 4.63 billion (2018)
- recurring EBITDA went up from 21% (2015) to 30% (2018)
- Net debt went down from € 921 million (2015) to € 237 million (2018)
- We stayed focused, invested in and divested some activities
- We set ambitious targets to reduce our environmental footprint
Accelerate & Expand
- We seek to maximize the number of lives we can positively impact, focusing on patients that can benefit most
- Pending regulatory decision, we plan to bring:
- Evenity™ (romosozumab) to patient living with osteoporosis at high risk of fracture, in close collaboration with Amgen
- midazolam to patient living with clusters seizures
- We continue the development of our late-stage assets:
- bimekizumab in psoriasis, psoriatic arthritis and axial spondyloarthritis
- padsevonil for drug resistant epilepsy patients
- rozanolixizumab for patients living with IgG-mediated autoimmune disease
- We strengthen our R&D to deliver new innovative compounds in shorter cycle time
- We identify and act on potential opportunities outside UCB – whether acquisition or divestment
Breakthrough & Lead
- We broaden patient access to Evenity™ and midazolam
- We hope to bring bimekizumab, padsevonil and rozanolixizumab to patients while mitigating the loss of exclusivity of Cimzia®, Vimpat® and Neupro®
- We deliver breakthrough solutions
1 National Institute of Neurological Disorders and Stroke – Accessed 23 January 2018
2 Epilepsy Foundation – Accessed 4 February 2019